Loading
A phase 1/2 trial of KSQ-001EX run by M.D. Anderson Cancer Center, active, not recruiting.
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06237881 by M.D. Anderson Cancer Center, with 15 participants planned, started 2024-01-31, primary completion expected 2027-01-01. Conditions recorded: Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms. Interventions recorded: KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/